Loading
NASDAQHealthcareBiotechnology
Latest quote
$3.40
−$0.30 · -8.11%
Aclaris Therapeutics, Inc., a biopharmaceutical firm operating in the United States, is currently in the clinical development phase, focused on creating novel therapeutic agents for various immune-inflammatory conditions. The company's operations are divided into two primary divisions: the Therapeutics segment, dedicated to discovering and progressing innovative treatments to address crucial unmet needs in immuno-inflammatory disorders; and the Contract Research segment, which delivers specialized laboratory services. The company's pipeline features several investigational compounds. Among these is Zunsemetinib, an MK2 inhibitor, being developed to treat moderate to severe cases of rheumatoid arthritis, psoriatic arthritis, and hidradenitis suppurativa. Another significant candidate is ATI-1777, a soft JAK 1/3 inhibitor, intended for the management of moderate to severe atopic dermatitis. Additionally, Aclaris is advancing ATI-2138, an ITK/TXK/JAK3 inhibitor, as a potential intervention for T cell-mediated autoimmune diseases; a Gut-Biased Program targeting inflammatory bowel disease; and ATI-2231, an MK2 inhibitor, for the treatment of pancreatic and metastatic breast cancer. Established in 2012, Aclaris Therapeutics, Inc. has its corporate headquarters situated in Wayne, Pennsylvania.
Previous close
$3.40
−$0.30 · -8.11%
Pre-market
$3.4657
+$0.0657 · +1.93%
Oct 8, 8:39 AM ET
Regular session · ET · Market data may be delayed.
Aclaris Therapeutics, Inc., a biopharmaceutical firm operating in the United States, is currently in the clinical development phase, focused on creating novel therapeutic agents for various immune-inflammatory conditions. The company's operations are divided into two primary divisions: the Therapeutics segment, dedicated to discovering and progressing innovative treatments to address crucial unmet needs in immuno-inflammatory disorders; and the Contract Research segment, which delivers specialized laboratory services. The company's pipeline features several investigational compounds. Among these is Zunsemetinib, an MK2 inhibitor, being developed to treat moderate to severe cases of rheumatoid arthritis, psoriatic arthritis, and hidradenitis suppurativa. Another significant candidate is ATI-1777, a soft JAK 1/3 inhibitor, intended for the management of moderate to severe atopic dermatitis. Additionally, Aclaris is advancing ATI-2138, an ITK/TXK/JAK3 inhibitor, as a potential intervention for T cell-mediated autoimmune diseases; a Gut-Biased Program targeting inflammatory bowel disease; and ATI-2231, an MK2 inhibitor, for the treatment of pancreatic and metastatic breast cancer. Established in 2012, Aclaris Therapeutics, Inc. has its corporate headquarters situated in Wayne, Pennsylvania.
Day range
Current $3.40
52-week range
Current $3.40
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
25
Expensive
Sentiment
74
Bullish
Risk
44
Elevated Risk
Momentum
71
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Aclaris Therapeutics, Inc., a biopharmaceutical firm operating in the United States, is currently in the clinical development phase, focused on creating novel therapeutic agents for various immune-inflammatory conditions. The company's operations are divided into two primary divisions: the Therapeutics segment, dedicated to discovering and progressing innovative treatments to address crucial unmet needs in immuno-inflammatory disorders; and the Contract Research segment, which delivers specialized laboratory services. The company's pipeline features several investigational compounds. Among these is Zunsemetinib, an MK2 inhibitor, being developed to treat moderate to severe cases of rheumatoid arthritis, psoriatic arthritis, and hidradenitis suppurativa. Another significant candidate is ATI-1777, a soft JAK 1/3 inhibitor, intended for the management of moderate to severe atopic dermatitis. Additionally, Aclaris is advancing ATI-2138, an ITK/TXK/JAK3 inhibitor, as a potential intervention for T cell-mediated autoimmune diseases; a Gut-Biased Program targeting inflammatory bowel disease; and ATI-2231, an MK2 inhibitor, for the treatment of pancreatic and metastatic breast cancer. Established in 2012, Aclaris Therapeutics, Inc. has its corporate headquarters situated in Wayne, Pennsylvania.
Day range
Current $3.40
52-week range
Current $3.40
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 7.83M USD | 18.72M USD | 31.25M USD | 29.75M USD | 6.76M USD |
| Cost of goods sold | 2.09M USD | 2.79M USD | 18.08M USD | 11.96M USD | 4.71M USD |
| Gross profit | 5.74M USD | 15.93M USD | 13.17M USD | 17.79M USD | 2.05M USD |
| Research and development | 52.65M USD | 33.59M USD | 98.38M USD | 77.81M USD | 43.81M USD |
| Selling, general, and administrative | 21.97M USD | 22.2M USD | 31.1M USD | 25.13M USD | 23.62M USD |
| Operating expenses | 82.11M USD | 157.86M USD | 110.53M USD | 107.65M USD | 91.77M USD |
| Interest income | 7.64M USD | 7.95M USD | — | — | — |
| Depreciation and amortization | 454K USD | 807K USD | 863K USD | 797K USD | 923K USD |
| Operating income | −76.38M USD | −141.93M USD | −97.36M USD | −89.85M USD | −89.72M USD |
| Net income | −64.92M USD | −132.07M USD | −88.48M USD | −86.91M USD | −90.87M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$10.60
211.76% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI25.67M0.00%2.3T USD0.03%$381.03-0.40%
iShares Russell 2000 ETFIWM11.52M0.01%78.56B USD0.19%$277.7-1.29%
Vanguard Extended Market ETFVXF8.87M0.01%95.4B USD0.05%$233.49-1.56%
Vanguard Russell 2000 ETFVTWO4.12M0.02%18B USD0.06%$112.21-1.26%
State Street SPDR S&P Pharmaceuticals ETFXPH4.08M0.84%462.1M USD0.35%$62.910.00%
iShares Russell 2000 Growth ETFIWO3.59M0.03%14.25B USD0.24%$355.37-1.43%
iShares Biotechnology ETFIBB3.15M0.03%10.4B USD0.44%$203.34+0.12%
Fidelity Enhanced Small Cap ETFFESM3.1M0.05%6.41B USD0.28%$45.22-1.14%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOState Street SPDR S&P Pharmaceuticals ETFXPHiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBFidelity Enhanced Small Cap ETFFESMAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
